TYBR Health, a Houston, Texas medical technology company, announced a $30m Series A on 21 July 2026. Vensana Capital and Mutual Capital Partners led the round, with participation from Neovate Capital Partners and existing investors.
The company did not disclose a valuation. Greg Banker of Vensana Capital and Liz Todia Zambory of Mutual Capital Partners join the board, alongside independent director Aaron Smith.
“Surgeons are exceptionally good at the structural repair, but the biology that follows is what determines how it heals.”Tim Keane, PhD, co-founder and CEO, TYBR Health
What TYBR does
TYBR makes the B3 GEL System, an FDA-cleared, flowable extracellular matrix hydrogel that protects tendons, ligaments, muscles and surrounding soft tissue as they heal after orthopaedic surgery. Houston Innovation Map said it helps protect tendons from scarring after surgery.
The product is used today in hand, wrist, shoulder, foot and ankle, and sports medicine procedures. Tim Keane, who holds a doctorate, is co-founder and chief executive. The company did not name other founders, give a founding year or disclose its headcount.
In the leaders' words
Keane said surgeons are exceptionally good at the structural repair but that the biology that follows determines how a patient heals. He said the financing lets the company reach more surgeons and generate the clinical evidence to move that shift forward.
Banker said TYBR has shown real commercial traction early and built a strong team. Zambory said Mutual Capital was excited to co-lead the round and support the company's growth. Vensana is based in Minneapolis, Mutual Capital in Cleveland and Neovate in Denver, according to Houston Innovation Map.
What the money is for
The company will use the funds to expand commercial access to B3 GEL, broaden the product's indications and run clinical studies on tissue protection during orthopaedic surgery. It did not disclose targets for sales, surgeon numbers or the size of earlier financing, and the announcement named no earlier rounds.
Product and market launch
Fundraise Insider reported that B3 GEL reached the US market in January 2026. It is built on an extracellular matrix technology platform, which the company says is designed to give surgeons practical tools for protecting healing tissue. The company describes its products as meant to improve healing and recovery after surgery.
None of the reports gave sales figures, hospital adoption numbers or clinical outcome data, so the company's commercial traction is described only in general terms. Banker of Vensana said TYBR had shown real commercial traction early.
Board and governance
As part of the financing, Banker and Zambory take board seats, joining independent director Aaron Smith. Vensana Capital is based in Minneapolis, Mutual Capital Partners in Cleveland and Neovate Capital Partners in Denver, Houston Innovation Map reported. The existing investors who took part were not named.
Because the announcement covered only this round, it did not state how much the company had raised before, and no earlier rounds are included in the history for this article.
Why the round matters
The Series A is the first financing the company has announced in the reports reviewed, and it comes about six months after the product reached the US market. The investors' comments focused on early commercial traction and on the clinical evidence the company plans to generate, which are the two uses of funds the company highlighted. The company did not publish a revenue figure, a surgeon count or a timeline for its planned studies.
Company website: tybrhealth.com